SCHEMBL10066680

SCHEMBL10066680

Cc1cc(/C=C/C(=O)N2CCC(C(N[C@H]3CC[C@H](c4c[nH]c5ccccc54)CC3)C(=O)O)CC2)cc(F)c1F

nearest known ligand 0.90

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
CCR2 P41597 20/20 0.90

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13596370 0.95 CCR2 (1.00) CCR2
SCHEMBL10066738 0.95 CCR2 (1.00) CCR2
Hydrochloric Acid SCHEMBL16161716 0.94 CCR2 (0.98) CCR2
Hydrochloric Acid SCHEMBL16161715 0.94 CCR2 (0.98) CCR2
SCHEMBL10066687 0.93 CCR2 (0.90) CCR2
SCHEMBL10066686 0.93 CCR2 (0.90) CCR2
SCHEMBL10066689 0.93 CCR2 (0.90) CCR2
SCHEMBL10066707 0.93 CCR2 (0.91) CCR2
SCHEMBL10066709 0.92 CCR2 (0.92) CCR2
SCHEMBL8985368 0.91 CCR2 (0.75) CCR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8921559-B2 4-substituted-cyclohexylamino-4-piperidinyl-acetamide antagonists of CCR2 JANSSEN PHARMACEUTICA NV (BE) 2014-12-30 US disclosed
US-20120142733-A1 4-SUBSTITUTED-CYCLOHEXYLAMINO-4-PIPERIDINYL-ACETAMIDE ANTAGONISTS OF CCR2 JANSSEN PHARMACEUTICA N.V. (BE) 2012-06-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120142733-A1 4-SUBSTITUTED-CYCLOHEXYLAMINO-4-PIPERIDINYL-ACETAMIDE ANTAGONISTS OF CCR2 CCR2, CCR5, CCR1 CCR2 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.